Why the study?
Does spironolactone 25 mg/day reduce proteinuria in patients with persistent proteinuria already treated with ACEIs or ARBs?
Does spironolactone 25 mg/day reduce proteinuria in patients with persistent proteinuria already treated with ACEIs or ARBs?
Add-on spironolactone significantly reduces proteinuria in patients on ACEI/ARB therapy, particularly those with preserved eGFR and without aldosterone escape, though it carries a risk of severe hyperkalemia in those with reduced eGFR.
Answers are grounded in this paper and cite their sources.
May support spironolactone add-on for UACR reduction in preserved eGFR without escape; leaves open confirmation and safety in RCTs.
BACKGROUND/AIMS: This study aimed to investigate the potential beneficial anti-proteinuric effect of an add-on aldosterone blockade and the impact of the aldosterone escape phenomenon. METHODS: We retrospectively analyzed data of 304 patients with persistent proteinuria, who were administered spironolactone (25 mg/day) after treatment with angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) for >3 months. Patients were divided according to their aldosterone levels during ACEI/ARB treatment into an escape group (plasma aldosterone >80 pg/mL, N=95, 31.5%) and a non-escape group (plasma aldosterone ≤80 pg/mL, N=209, 68.5%) and according to their urine albumin-to-creatinine ratio (UACR) and estimated glomerular filtration rate (eGFR). RESULTS: After 12 months, the UACR decreased significantly in patients with 1≤UACR<3.5 g/g Cr, UACR ≥3.5 g/g Cr, and eGFR ≥60 mL/min/1.73 m2, and in the non-escape group. Severe hyperkalemia (K≥7.0 mEq/L) developed in 9 of 137 patients with eGFR<60 mL/min/1.73 m2 (6.5%) and in none of the 167 patients with eGFR ≥60 mL/min/1.73 m2. CONCLUSIONS: Proteinuria decreased significantly after add-on spironolactone treatment in patients with 1≤UACR<3.5 g/g Cr, UACR ≥3.5 g/g Cr, and eGFR ≥60 mL/min/1.73 m2, and in the non-escape group. The anti-proteinuric effect of spironolactone may vary according to the degree of albuminuria, impaired eGFR, and aldosterone escape.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: